NEW YORK (360Dx) – Roche today announced the cobas m 511 dedicated hematology testing solution has received CE marking, allowing it to be marketed in countries that recognize the designation.
Roche is launching the integrated hematology analyzer, marking Roche Diagnostics' entry into the hematology market.
According to the company, current hematology testing requires larger blood samples from patients, which then need to be run across several different systems. As a result, testing is labor and time intensive and can provide inconsistent results.
The cobas m 511 combines three components of the testing process — a digital morphology analyzer, cell counter,and classifier — into a streamlined solution, which prepares, stains, and analyzes microscopy blood slides.
Roche said that its system provides test results with greater accuracy and consistency, compared to current technologies. The cobas m 511 identifies, counts, isolates, and categorizes white blood cells, red blood cells, red blood cells, and platelets, then presents the digital images of the cell types.
"With this launch, patients will benefit from a faster and more accurate diagnosis of blood diseases, as diverse as anemia and leukemia," Roche Diagnostics CEO Roland Diggelmann said in a statement.